

## Capillary Malformation-Arteriovenous Malformation

Capillary malformation-arteriovenous malformation syndrome (CM-AVM) is a disorder of the vascular system characterized by enlarged capillaries that appear as small, round dots on the skin. Genetic testing can confirm diagnosis of *RASA1*-related CM-AVM disorder (CM-AVM1), or an *EPHB4*-related CM-AVM disorder (CM-AVM2), in individuals with symptoms suggestive of CM-AVM.

### DISEASE OVERVIEW

#### Incidence

- ~1/20,000 for CM-AVM1
- ~1/12,000 for CM-AVM2

#### Symptoms/Manifestations

- Multifocal CMs; commonly localized on skin of the trunk, limbs, or face
  - Fast flow lesions
    - AVM, arteriovenous fistula (AVF), and vein of Galen malformation located in the brain, spine, skin, or muscle may cause life-threatening complications
      - Bleeding
      - Congestive heart failure
      - Neurological consequences
    - In Parkes Weber Syndrome (PKWS), diffuse subcutaneous/intramuscular micro AVFs associated with hypertrophy of the involved extremity
  - Lymphatic abnormalities
  - Recurrent epistaxis (CM-AVM2, but uncommon)
  - Telangiectasias – dermal (CM-AVM2, but less common than CMs)

### GENETICS

#### Genes

*EPHB4* and *RASA1*

#### Inheritance

Autosomal dominant

#### Penetrance

- *EPHB4* – 93% (Amyere, 2017)
- *RASA1* – 90-95%

#### De novo Variants

~33% of cases for *RASA1*

#### Variants

- 92% of *RASA1* pathogenic variants detectable by sequencing
- 8% of *RASA1* pathogenic variants detectable by deletion/duplication analysis

### TESTS TO CONSIDER

[Capillary Malformation-Arteriovenous Malformation \(EPHB4 and RASA1\) Sequencing, and \(RASA1\) Deletion/Duplication 3001132](#)

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Most comprehensive DNA test for CM-AVM (CM-AVM1 and CM-AVM2)

[RASA1-Related Disorders \(RASA1\) Sequencing and Deletion/Duplication 2007852](#)

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Preferred DNA test for *RASA1*-related disorders (CM-AVM1) only

[RASA1-Related Disorders \(RASA1\) Sequencing 2002730](#)

Method: Polymerase Chain Reaction/Sequencing

DNA test for *RASA1*-related disorders (CM-AVM1) only

[Capillary Malformation-Arteriovenous Malformation 2 \(EPHB4\) Sequencing 3001129](#)

Method: Polymerase Chain Reaction/Sequencing

DNA test for *EPHB4*-related CM-AVM (CM-AVM2) only

#### Related Tests

[Hereditary Hemorrhagic Telangiectasia \(HHT\) Panel, Sequencing and Deletion/Duplication 2009337](#)

Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Most comprehensive test to determine the cause of a telangiectasia/AVM disorder

[Vascular Malformations Panel, Sequencing and Deletion/Duplication 2007384](#)

## TEST INTERPRETATION

### Sensitivity/Specificity

- Clinical sensitivity for CM-AVM – not well established and varies based on clinical manifestations; estimates based on available publications
  - *EPHB4*
    - Sequencing – at least 15%
      - Detected in 15% of individuals with sporadic or familial CMs with or without fast-flow lesions (Amyere, 2017)
    - Deletion/duplication – unknown
  - *RASA1*
    - Sequencing – ~30-70%
      - Detected in 30% of consecutive cases with or without CMs (Wooderchak-Donahue, 2012), with higher detection rate in individuals with multifocal CMs
      - Detected in 70% of individuals with multifocal CMs with or without fast-flow lesions (Revenu, 2013)
    - Deletion/duplication – ~8% (Bayrak-Toydemir, 2016)
- Analytical sensitivity/specificity for sequencing of *EPHB4* and *RASA1*, and MLPA of *RASA1* – 99%

### Limitations

- Diagnostic errors can occur due to rare sequence variations
- Not determined or evaluated
  - Large deletions/duplications in *EPHB4*
  - Regulatory region and deep intronic variants
  - Breakpoints for large deletions/duplications identified in *RASA1*
  - Variants in genes other than *EPHB4* and *RASA1*

## REFERENCES

- Amyere M, Revenu N, Helaers R, Pairet E, Baselga E, Cordisco M, Chung W, Dubois J, Lacour J, Martorell L, Mazereeuw-Hautier J, Pyeritz RE, Amor DJ, Bisdorff A, Blei F, Bombei H, Domp martin A, Brooks D, Dupont J, González-Enseñat MA, Frieden I, Gérard M, Kvarnung M, Hanson-Kahn AK, Hudgins L, Léauté-Labrèze C, McCuaig C, Metry D, Parent P, Paul C, Petit F, Phan A, Quere I, Salhi A, Turner A, Vabres P, Vicente A, Wargon O, Watanabe S, Weibel L, Wilson A, Willing M, Mulliken JB, Boon LM, Vikkula M. [Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation \(CM-AVM2\) Deregulating RAS-MAPK Signaling](#). *Circulation*. 2017; 136(11): 1037-1048. PubMed
- Bayrak-Toydemir P, Stevenson D. [RASA1-Related Disorders](#). In: Pagon RA, Adam MP, Ardinger HH, et al., editors. *GeneReviews*, University of Washington, 1993-2018. Seattle, WA [Last Update: Oct 2016; Accessed: Nov 2018]
- Revenu N, Boon LM, Mendola A, Cordisco MR, Dubois J, Clapuyt P, Hammer F, Amor DJ, Irvine AD, Baselga E, Domp martin A, Syed S, Martin-Santiago A, Ades L, Collins F, Smith J, Sandaradura S, Barrio VR, Burrows PE, Blei F, Cozzolino M, Brunetti-Pierri N, Vicente A, Abramowicz M, Désir J, Vilain C, Chung WK, Wilson A, Gardiner CA, Dwight Y, Lord DJ, Fishman L, Cytrynbaum C, Chamlin S, Ghali F, Gilaberte Y, Joss S, Boente MD, Léauté-Labrèze C, Delrue M, Bayliss S, Martorell L, González-Enseñat M, Mazereeuw-Hautier J, O'Donnell B, Bessis D, Pyeritz RE, Salhi A, Tan OT, Wargon O, Mulliken JB, Vikkula M. [RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation](#). *Hum Mutat*. 2013; 34(12): 1632-41. PubMed
- Wooderchak-Donahue W, Stevenson DA, McDonald J, Grimmer F, Gedge F, Bayrak-Toydemir P. [RASA1 analysis: clinical and molecular findings in a series of consecutive cases](#). *Eur J Med Genet*. 2012; 55(2): 91-5. PubMed
- Wooderchak-Donahue WL, Johnson P, McDonald J, Blei F, Berenstein A, Sorscher M, Mayer J, Scheuerle AE, Lewis T, Grimmer F, Richter GT, Steeves MA, Lin AE, Stevenson DA, Bayrak-Toydemir P. [Expanding the clinical and molecular findings in RASA1 capillary malformation-arteriovenous malformation](#). *Eur J Hum Genet*. 2018; 26(10): 1521-1536. PubMed

## RELATED INFORMATION

[Hereditary Hemorrhagic Telangiectasia - HHT](#)

Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Preferred DNA test to confirm clinical diagnosis of a heritable vascular malformation disorder

[Familial Mutation, Targeted Sequencing 2001961](#)

Method: Polymerase Chain Reaction/Sequencing

Useful when a pathogenic familial variant identifiable by sequencing is known

